Kamal Ghorui
Stock market recommendations: Ipca Laboratories, and AU Small Finance Bank are the stocks that Motilal Oswal Wealth Management Research Desk recommends buying for the week starting March 30, 2026. Target prices and potential upsides are listed below:
Ipca LaboratoriesIpca Laboratories is witnessing improving growth visibility driven by a recovery in its domestic formulations business and a gradual pickup in exports. The company is strengthening its domestic portfolio through therapy expansion in cardiology, pain management, and entry into high-end dermatology, while reinforcing key brands like Zerodol. Export growth is supported by increasing traction in branded markets and a steady ramp-up in generics, aided by product relaunches in the United States and participation in European tenders. The integration of the Unichem business is progressing, with focus on improving cost efficiencies through API integration and rebuilding the product pipeline, although near-term performance remains impacted by pricing pressure. Overall, improving operating leverage, portfolio optimization, and better execution across segments position the company for steady earnings growth.AU Small Finance BankAU Small Finance Bank’s transition from a SFB to a universal bank expands its addressable market across retail, MSME, and mid-corporate lending, while lower priority sector requirements and broader product capabilities improve portfolio flexibility, cross-selling opportunities, & long-term return potential. A granular deposit base, improving CASA mix, and expanding network of 2,700+ touchpoints support liability growth and operating leverage. The secured-heavy loan portfolio and disciplined underwriting are expected to keep credit costs contained, supporting sustainable long-term profitability. Loans are expected to grow at ~24% CAGR over FY26-28, driven by a strong branch-led distribution network and expansion across secured lending segments. This, along with moderating funding costs and stable asset quality, is likely to drive ~36% earnings CAGR over FY26-28.(Disclaimer: Recommendations and views on the stock market, other asset classes or personal finance management tips given by experts are their own. These opinions do not represent the views of The Times of India)
